Right Brain Bio

Right Brain Bio is a private, pre-revenue biotech challenging the long-standing dopamine deficiency model of Parkinson's disease. The company's core discovery is that excess intracellular dopamine, not a lack of it, drives neurodegeneration, leading to its therapeutic candidate RB-190, a drug that lowers dopamine synthesis. With a seasoned leadership team including former FDA officials and Parkinson's experts, and FDA confirmation that RB-190 is ready for Phase 2 trials, the company is positioned to test its revolutionary hypothesis in patients. Success could fundamentally shift the treatment paradigm for millions of Parkinson's patients worldwide.

Targeted neurochemical modulation platform based on the hypothesis that intraneuronal dopamine excess drives Parkinson's pathology. The platform focuses on identifying compounds that lower dopamine synthesis inside neurons to reverse neurodegeneration.

Right Brain Bio competes in the crowded Parkinson's disease therapeutic space, which includes large pharma companies offering symptomatic treatments and numerous biotechs pursuing disease-modification through various mechanisms (e.g., alpha-synuclein targeting, neuroinflammation, GLP-1 agonists). Its key differentiation is its unique, contrarian pathogenic hypothesis focusing on intracellular dopamine toxicity, which sets it apart from both standard dopamine replacement therapies and most novel investigative approaches.